Stock Update (NYSE:BAX): FDA Approves Baxter’s OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired Hemophilia A
October 24, 2014 at 09:00 AM EDT
[Business Wire] – Baxter International Inc. today announced that the United States Food and Drug Administration has approved OBIZUR [Antihemophilic Factor , Porcine Sequence] for the treatment of bleeding episodes in adults with . . . → Read More: Stock Update (NYSE:BAX): FDA Approves Baxter’s OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired Hemophilia A Similar Articles: Company Update: Baxter International Inc (NYSE:BAX) – Baxter’s Third Quarter Financial Results Exceed Guidance Company Update: Baxter International Inc (NYSE:BAX) – Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company Stock Update: Baxter International Inc (NYSE:BAX) – Baxter to Present at Morgan Stanley Global Healthcare Conference